VA
NTLA icon

Vident Advisory’s Intellia Therapeutics NTLA Stock Holding History

Vident Advisory’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,621
Closed -$439K – 1504
2024
Q2 		$439K Buy
19,621
+2,133
+12% +$50.8K 0.01% 966
2024
Q1 		$481K Buy
17,488
+1,023
+6% +$28.4K 0.01% 834
2023
Q4 		$502K Buy
16,465
+691
+4% +$19.9K 0.01% 775
2023
Q3 		$499K Buy
+15,774
New +$612K 0.02% 705

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vident Advisory's NTLA Position: Q3 2024 in Review

Vident Advisory sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 19,621 shares — an estimated $439K sold.

Vident Advisory first reported a position in NTLA in Q3 2023 and held it in 4 quarters. The position peaked at $502K in Q4 2023. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Vident Advisory reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Vident Advisory sold 19,621 Intellia Therapeutics shares in Q3 2024, an estimated $439K.
  • Vident Advisory first reported a position in Intellia Therapeutics in Q3 2023 and held it in 4 quarters.
  • Vident Advisory's Intellia Therapeutics position peaked at $502K in Q4 2023.
  • 283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Vident Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.